Tags : Active Psoriatic Arthritis

Janssen Reports Submission of sBLA to the US FDA for

Shots: The sBLA is based on two P-III DISCOVER-1 & 2 studies assessing Tremfya (SC) in 381 & 739 patients with active PsA including prior treated patients with anti-TNF therapy and continued through 52wks. & biologic-naïve patients planning to continue through 100wks. respectively The P-III DISCOVER-1 & 2 studies resulted in meeting their 1EPs i.e, […]Read More

Eli Lilly to Report Positive Results of Taltz (ixekizumab) in

Shots: The P-IIIb/IV SPIRIT-H2H study results involve assessing of Taltz vs Humira (adalimumab) in 566 patients with PsA who are biologic DMARD-naive for 52wks. The P-IIIb/IV SPIRIT-H2H study results: met its 1EPs & 2Eps i.e, @24wks. reduction by 50% in disease activity as defined by ACR50; PASI100 (36% vs 28%) & superior to Humira, ACR50 […]Read More